ReviewJournal of diabetes and metabolic disorders2025
Emerging insights of decoding the genetic blueprint, molecular mechanisms, and future horizons in precision medicine for the treatment of type 2 diabetes.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular pathways, tissue-specific roles, and therapeutic opportunities in mitochondrial resilience-based strategies for insulin resistance.Frontiers in clinical diabetes and healthcare · 2026Review
- Inter-Individual Heterogeneity in Aerobic Training Adaptations: Systematic Review of the Evidence Base for Personalized Exercise Prescription.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2D) is a complex, multifactorial metabolic disorder that poses a significant global health challenge. Despite advancements in conventional therapies, limitations persist in achieving optimal glycemic control, primarily due to the disease's heterogeneity. Precision medicine represents a paradigm shift in the management of T2D by tailoring treatments to individual genetic, molecular, and environmental factors. This review examines the genetic and molecular mechanisms underlying T2D and their implications for precision medicine, highlighting critical advancements in genomic and multi-omics technologies, including pharmacogenomics and transcriptomics. It also discusses the limitations of traditional therapeutic approaches and identifies the unmet needs in diabetes care. Furthermore, this review examines future directions, including the integration of artificial intelligence, microbiome analysis, and digital health tools, to advance precision medicine in T2D. By bridging research and clinical practice, this review aims to inspire innovative strategies that redefine the landscape of T2D management and offer hope for improved patient outcomes through personalized interventions. Graphical abstract:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.